Segment Information (Tables)

6 Months Ended

Jun. 30, 2023

Segment Information

Summary of results of operations by reportable segment

	Prescription		Medical
For the Six Months Ended June 30, 2023	Medications		Devices		Corporate		Consolidated
Net sales	$	2,490,686	$	2,021,297	$	—	$	4,511,983
Cost of goods sold		257,721		806,878		—		1,064,599
Selling, general and administrative expenses		754,993		905,442		2,719,796		4,380,231
Research and development expenses		1,130,338		55,330		—		1,185,668
Depreciation and amortization expense		1,150,939		502,651		—		1,653,590
Interest income		—		—		(119,241)		(119,241)
Interest expense		—		—		278,966		278,966
Net loss	$	(803,305)	$	(249,004)	$	(2,879,521)	$	(3,931,830)

	Prescription		Medical
For the Six Months Ended June 30, 2022	Medications		Devices		Corporate		Consolidated
Net sales	$	4,856,941	$	1,794,744	$	—	$	6,651,685
Cost of goods sold		489,007		632,553		—		1,121,560
Selling, general and administrative expenses		3,440,168		884,538		2,789,636		7,114,342
Gain on settlement with Vivus		(3,389,941)		—		—		(3,389,941)
Research and development expenses		750,296		76,306		—		826,602
Depreciation and amortization expense		2,539,328		582,412		—		3,121,740
Change in fair value of derivative liability		—		—		(460,000)		(460,000)
Interest expense		—		—		303,398		303,398
Net income (loss)	$	1,028,083	$	(381,065)	$	(2,633,034)	$	(1,986,016)

Summary of net sales by geographic region

	For the Three Months Ended				For the Six Months Ended
	June 30,				June 30,
Net sales	2023		2022		2023		2022
United States	$	1,597,829	$	3,861,915	$	3,756,599	$	5,907,539
International		396,182		324,601		755,384		744,146
	$	1,994,011	$	4,186,516	$	4,511,983	$	6,651,685

Summary of assets by reportable segment and reconciliation of segment assets to consolidated assets

The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of June 30, 2023, are summarized as follows:

	Prescription		Medical
	Medications		Devices		Consolidated
Intangible assets, net	$	6,032,875	$	4,563,129	$	10,596,004
Total segment assets	$	22,218,785	$	6,508,323	$	28,727,108

The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2022, are summarized as follows:

	Prescription		Medical
	Medications		Devices		Consolidated
Intangible assets, net	$	7,178,704	$	5,065,780	$	12,244,484
Total segment assets	$	25,831,048	$	6,590,166	$	32,421,214